News for Sanofi Stock (SNY)

Sanofi: EPS Momentum Driven By Dupixent, Vaccines Day On Tap

Seeking Alpha • 06/29/23

Sanofi reaffirms target to deliver over $10.9 bln in annual vaccine sales by 2030

Reuters • 06/29/23

Sanofi says it's back to the drawing board on mRNA flu vaccines

Reuters • 06/29/23

Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

GlobeNewsWire • 06/29/23

Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study

Zacks Investment Research • 06/28/23

Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

GlobeNewsWire • 06/27/23

Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

GlobeNewsWire • 06/25/23

Press Release: Availability of the Q2 2023 Memorandum for modelling purposes

GlobeNewsWire • 06/22/23

Sanofi (SNY) Could Be a Great Choice

Zacks Investment Research • 06/21/23

2 Biopharma Stocks Making Big Moves Tuesday

The Motley Fool • 06/20/23

Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim

GlobeNewsWire • 06/20/23

Sanofi (SNY) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

Seeking Alpha • 06/14/23

Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients

GlobeNewsWire • 06/13/23

Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants

GlobeNewsWire • 06/08/23

US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy

Reuters • 06/08/23

FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection

Market Watch • 06/08/23

International Wide-Moat Stocks On Sale - The June 2023 Heat Map

Seeking Alpha • 06/08/23

The 7 Most Reliable Dividend Stocks to Buy Now

InvestorPlace • 06/06/23

US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy

Reuters • 06/06/23

Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan

GlobeNewsWire • 06/01/23

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

Zacks Investment Research • 05/31/23

Was This $3 Billion Deal a Wise Move for Sanofi?

The Motley Fool • 05/31/23

Sanofi announces positive data for frexalimab product to treat multiple sclerosis

Reuters • 05/31/23

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

GlobeNewsWire • 05/31/23

Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

GlobeNewsWire • 05/25/23